FDA, New Products

Achaogen hits, then misses: FDA OKs Zemdri for cUTIs, but rejects second indication

Following an advisory committee’s suggestions back in May, the FDA has handed one approval — and one rejection — to Achaogen’s lead antibiotic.

Blake Wise

Although somewhat expected, the news appears to be disappointing Achaogen’s investors. The company’s stock $AKAO is down 11% in pre-market trading.

Achaogen’s drug, which now goes by the brand name Zemdri (plazomicin), has been OK’ed to treat complicated urinary tract infections. However, the agency issued a complete response letter (CRL) in response to Achaogen’s bid to treat bloodstream infections, citing lack of effectiveness of the drug in a clinical study. The company said it plans to meet with the FDA to see if there’s a “feasible resolution” to address the CRL.

A large part of what seems to have doomed Achaogen’s plans for the bloodstream infections indication was a smaller-than-expected sample size that complicated statistical analysis. The biotech had to amend protocols for its Phase III study (ACHN-490-007) because it could only enroll 37 patients out of the planned 286. That resulted in statistical limitations proving Zemdri’s superior efficacy to colistin in the comparator arm — a point of discussion among the FDA’s advisory committee on the drug earlier this year.

For cUTI, on the other hand, committee members had no problem unanimously endorsing Zemdri based on a study that showed it was noninferior to meropenem, even considering a larger margin of 15% (versus a conventional 10%) the FDA sanctioned.

“The approval of Zemdri marks a significant milestone for Achaogen and we are excited to offer healthcare practitioners a new treatment option for patients with certain serious bacterial infections,” said Achaogen’s CEO Blake Wise in a statement. “Zemdri is designed to retain its potent activity in the face of certain difficult-to-treat multidrug resistant infections, including CRE and ESBL- producing Enterobacteriaceae.”

Image: McFarlene Architects


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,500+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->